Please assess the completion status of the following clinical trial:

Trial Title: Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is ambulatory male or female~* Patient's body mass index score is \> 20 and \< 40 kg/m\^2 at the Screening Visit~* Women of childbearing potential must have a negative pregnancy test at the time of screening and check-in and must agree to use protocol-specified contraception throughout the duration of the study~* Patient's health is stable with no clinically significant findings on physical examination~* Patient has type 2 (ie, adult onset) diabetes mellitus diagnosed by a physician or nurse practitioner \> 6 months before the Screening Visit, is on a stable glycemic control medication, and protocol specified hemoglobin (Hb)A1c values at the Screening Visit~* Patient has hypertension diagnosed by a physician or nurse practitioner \> 6 months before the Screening Visit, and blood pressure (BP) within the protocol's acceptable range~* Patients must be on a stable regimen for hypertension control that includes an angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB), stable for 28 days~* Other inclusion criteria per protocol~Exclusion Criteria:~* Patient has a clinically significant active or unstable medical condition that, in the opinion of the Investigator, would preclude trial participation~* Patient is on medication(s) that, when co-administered with a sGC stimulator, could increase the risk of hypotension~* Patient has evidence of severe or active end-organ damage~* Patient is an active smoker or has used any nicotine-containing products (cigarettes, e-cigarettes, vape pens, cigars, chewing tobacco, gum, patches) during the 6 months before Check-in. Use of nicotine is excluded during the study until after the End of Trial Visit.~* Other exclusion criteria per protocol

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- IW-1973 QD/QD (Type: EXPERIMENTAL): On Days 1-14: IW-1973 40 mg taken once daily (QD) in morning (AM) and placebo taken QD at night (PM).
- IW-1973 BID (Twice Daily)/QD (Type: EXPERIMENTAL): On Days 1-7: IW-1973 20 mg taken in AM and IW-1973 20 mg taken in PM. On Days 8-14: IW-1973 40 mg taken QD in AM and placebo taken QD in PM.
- Placebo (Type: PLACEBO_COMPARATOR): On Days 1-14: Placebo taken in AM and in PM.

Based on this trial design, predict the completion outcome and termination type (if applicable).